Lates News

Puyin International Securities released a research report on May 8th, giving BeiGene (688235.SH) a buy rating. The reasons for the rating mainly include: 1) 1Q25 revenue meets expectations, achieving quarterly GAAPOP profit and net profit slightly better than expected ahead of schedule, the company maintains its full-year guidance unchanged; 2) Sales of zebutinib overseas continue to grow rapidly; 3) Gross margin meets expectations, operational efficiency continues to improve. (Daily Economic News)